1、White PaperBeneath the Surface:Unravelling the True Value of Generic Medicines April 2024PER TROEIN,Vice President,Strategic Partners,IQVIA MAX NEWTON,Engagement Manager,Strategic Partners(GS&AR),IQVIA MARCO TRAVAGLIO,Consultant,Global Supplier&Association Relations,IQVIA KELSEY STODDART,Consultant,

2、Global Supplier&Association Relations,IQVIA2|Beneath the Surface:Unravelling the True Value of Generic Medicines European PerspectivesTable of contentsExecutive summary 1 Introduction 2Generic medicines support predictable and sustainable pharmaceutical spending 5Generic medicines continue to delive

3、r savings long after loss of exclusivity 5Large opportunities for cost savings can be expected 5Generic entry contributes to reducing overall co-payments 6Generic medicines are key access catalysts 8Generic medicines doubled access in chronic disease areas 8Access benefits differ based on therapeuti

4、c category and market dynamics 8Generic medicines help to reduce disease burden in underserved markets 11Generic medicines have an important role to play in future health outcomes 12Generic medicines support supply chain resilience 12Multisource generic products mitigate the impact of shortages 129

5、In 10 critical medicines are generic medicines 13After loss of exclusivity,generic medicines are often the only option 14Generic manufacturers continue to invest in europe 15The off-patent sector supports innovation 17VAMs directly offer a range of unique benefits to patients 17Generic companies are

6、 progressing environmentally sustainable practices 18Generic savings cycle continues innovation 18Challenges and long-term outlook 19References 20About the authors 22 |1 |1Today,generic medicines are an integral part of the healthcare system and demand for these products continues to rise.However,wh